GeoVax Labs, Inc. — 2012 Form 10-K
Reporting period: Fiscal year ended December 31, 2012. The filing also provides unaudited fourth-quarter results. GeoVax is a development-stage biotechnology company developing preventive and therapeutic HIV vaccines; it had no product sales or approved products.
Financial performance and liquidity
| Metric | 2012 | 2011 |
|---|---|---|
| Revenue (NIH and other grants) | $2.66 million | $4.90 million |
| Research and development expense | $3.04 million | $4.28 million |
| General and administrative expense | $1.75 million | $2.97 million |
| Net loss | $2.14 million | $2.35 million |
| Net loss per share | $0.12 | $0.15 |
| Net cash used in operating activities | $2.44 million | $0.30 million |
| Cash and cash equivalents at year-end | $1.04 million | $1.17 million |
| Working capital at year-end | $1.02 million | $0.48 million |
| Total assets at year-end | $1.48 million | $1.65 million |
| Stockholders’ equity at year-end | $1.15 million | $0.70 million |
Grant revenue was the company’s sole revenue source and is recognized as related costs are incurred. There were no product revenues, meaningful commercial margins, or long-term debt. Current liabilities were $327,035; contractual obligations totaled approximately $764,000, including $510,000 of firm purchase commitments expected to fall due in 2013.
Fourth-quarter 2012 grant revenue was $459,566 and net loss was $610,085, or $0.03 per share. In fourth-quarter 2011, grant revenue was $956,844 and net loss was $1.15 million, or $0.08 per share.
Changes versus prior year
- Annual grant revenue fell about 46%, while R&D expense declined about 29% and G&A expense about 41%. Net loss narrowed about 9%.
- Operating cash use rose substantially from 2011. Management attributed the unusually low 2011 use partly to favorable working-capital movements, including changes in deferred offering costs and payables.
- Cash declined by approximately $132,000 during 2012. The company raised about $2.0 million net from a March preferred-stock and warrant financing, alongside proceeds from common-stock sales.
- NIH awarded a new $1.9 million grant in September 2012 for clade C vaccine development. At year-end, about $1.4 million remained available from that grant and about $1.6 million from the earlier $20.4 million NIH award.
Pipeline, outlook, and risks
- The preventive clade B vaccine’s Phase 2a trial was completed in 2012. GeoVax reported that both tested regimens appeared safe and well tolerated, with different immune-response profiles; full publication was expected by the end of 2013.
- A 48-participant Phase 1 trial of a second-generation, GM-CSF-adjuvanted preventive vaccine was fully enrolled and expected to conclude in late 2013. A Phase 2 efficacy trial remained contingent on trial results, design, and government funding.
- A nine-participant therapeutic treatment-interruption study completed enrollment; initial data were expected in late 2013. A separate NIH-supported therapeutic combination-trial was planned to begin in mid-2013.
- Management expected available working capital and NIH grant funds to support planned operations into the first quarter of 2014, and anticipated seeking additional capital during 2013. Funding was not assured; a shortfall could force delays, reduced operations, or other strategic alternatives.
- Key risks include clinical or regulatory failure and delay, dependence on NIH/HVTN support and third-party manufacturers, continuing losses and financing needs, competition, and patent or licensing risks. The company had no commercial manufacturing, sales, or marketing capabilities.
- After year-end, in January 2013, certain Series B warrant exercise prices were reduced from $0.75 to $0.60; exercise of 1,766,667 warrants generated $1.06 million. The modification resulted in a reported $218,551 expense in January 2013. Additional warrant, preferred-stock, and option-related dilution is possible.
Investor facts to verify
- Review the complete audited statements and notes, particularly the company’s cash runway, grant restrictions and expiration dates, and post-year-end financing activity.
- Track clinical trial results, regulatory progress, and whether NIH/HVTN funding and a Phase 2 efficacy-trial plan are secured.
- Assess potential dilution from outstanding warrants, options, and convertible preferred stock, including the January 2013 warrant repricing.
- Reconcile the filing’s inconsistent 2010 net-loss figures: the selected financial data table gives $2.47 million, while the audited statements and MD&A give $2.75 million.